✦ LIBER ✦

Final results of a phase II study ofnab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

✍ Scribed by Christopher Lobo; Gilberto Lopes; Odalys Baez; Aurelio Castrellon; Annapoorna Ferrell; Connie Higgins; Erin Hurley; Judith Hurley; Isildinha Reis; Stephen Richman; Pearl Seo; Orlando Silva; Joyce Slingerland; Keleni Tukia; Catherine Welsh; Stefan Glück

Publisher: Springer US
Year: 2010
Tongue: English
Weight: 268 KB
Volume: 123
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-010-1002-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The efficacy and safety of gemcitabine p

The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype

✍ Kenjiro Aogi; Masayuki Yoshida; Yoshiaki Sagara; Shunji Kamigaki; Minoru Okazaki 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 311 KB

A phase II study of weekly irinotecan as

A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer

✍ Hideki Ueno; Takuji Okusaka; Akihiro Funakoshi; Hiroshi Ishii; Kenji Yamao; Osam 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 328 KB

Non-pegylated liposomal doxorubicin comb

Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial

✍ S. Del Barco; R. Colomer; L. Calvo; I. Tusquets; E. Adrover; P. Sánchez; J. Rifà 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 220 KB

Results of a phase II study of pemetrexe

Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer

✍ Nicholas J. Robert; Paul R. Conkling; Mark A. O’Rourke; Paul R. Kuefler; Kristi 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 234 KB

A phase II study of paclitaxel plus carb

A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma

✍ Edith A. Perez; David W. Hillman; Philip J. Stella; James E. Krook; Lynn C. Hart 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 3 views

## BACKGROUND. This Phase II multicenter study evaluated the efficacy and toxicity of paclitaxel (200 mg/m 2 by 3-hour infusion) with carboplatin (area under the curve 6 mg/mL per minute) administered every 3 weeks as first-line therapy for women with metastatic breast carcinoma. ## METHODS. Eligi

Multicenter phase II study of trastuzuma

Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer

✍ M. Venturini; C. Bighin; S. Monfardini; F. Cappuzzo; N. Olmeo; A. Durando; F. Pu 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 218 KB